American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering, LK, Baker, CJ, Kimberlin, DW, Long, SS (eds). Red Book: 2012 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, 2012: 609–617.
Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet
2012; 380: 2095–2128.
Hall, CB, Weinberg, GA, Blumkin, AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics
2013; 132: e341–e348.
MacDonald, NE, Hall, CB, Suffin, SC, Alexson, C, Harris, PJ, Manning, JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med
1982; 307: 397–400.
Geskey, JM, Cyran, SE. Managing the morbidity associated with respiratory viral infections in children with congenital heart disease. Int J Pediatr
2012; 2012: 646780.
Jung, JW. Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey. Korean J Pediatr
2011; 54: 192–196.
Cabalka, AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J
2004; 23: S41–S45.
Boyce, TG, Mellen, BG, Mitchel, EF Jr., Wright, PF, Griffin, MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr
2000; 137: 865–870.
Feltes, TF, Cabalka, AK, Meissner, HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr
2003; 143: 532–540.
Robinson, JL, Le Saux, N. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health
2015; 20: 321–333.
Chantepie, A, Bureau de la Filiale de Cardiologie Pediatrique de la Societe Francaise de Cardiologie. Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease: recommendations from the French Paediatric Cardiac Society [in French]. Arch Pediatr
2004; 11: 1402–1405.
Liese, J. RSV prophylaxis with palivizumab in high-risk children – update German national guidelines 2008. Monatsschr Kinderheilkd
2009; 157: 61–64.
Nakazawa, M, Saji, T, Ichida, F, Oyama, K, Harada, K, Kusuda, S. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int
2006; 48: 190–193.
Bollani, L, Baraldi, E, Chirico, G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr
2015; 41: 97.
Medrano Lopez, C, Garcia-Guereta, L, Fernandez Pineda, L, et al. Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology [in Spanish]. An Pediatr (Barc)
2010; 72: 432.e1–e13.
Society of Neonatology Taiwan and Taiwan Society of Pediatric Cardiology. Recommendations for palivizumab vaccination. In: Recommendations for Prevention of RSV Infection in Taiwan. Society of Neonatology Taiwan and Taiwan Society of Pediatric Cardiology, Taipei, 2015: 19–22.
Tulloh, R, Marsh, M, Blackburn, M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young
2003; 13: 420–423.
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics
2014; 134: 415–420.
American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics
2003; 112: 1442–1446.
Hsu, CC, Sandford, BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval
2007; 12: 1–8.
Tulloh, RM, Feltes, TF. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease. Cardiol Young
2005; 15: 274–278.
Andabaka, T, Nickerson, JW, Rojas-Reyes, MX, Rueda, JD, Bacic Vrca, V, Barsic, B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev
2013; 4: CD006602.
Hussman, JM, Lanctot, KL, Paes, B. The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. J Med Econ
2013; 16: 115–124.
Wang, D, Bayliss, S, Meads, C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess
2011; 15: iii–iv; 1–124.
Wang, D, Cummins, C, Bayliss, S, Sandercock, J, Burls, A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess
2008; 12: iii, ix–x, 1–86.
McKenna, HP. The Delphi technique: a worthwhile research approach for nursing?
J Adv Nurs
1994; 19: 1221–1225.
27. Howick J, Chalmers I, Glasziou P, et al. ‘The Oxford Levels of Evidence 2’. Oxford Centre for Evidence-Based Medicine, 2011. Retrieved September 1, 2016, from http://www.cebm.net/index.aspx?o=5653.
Bellavance, M, Rohlicek, CV, Bigras, JL, et al. Palivizumab use among children with congenital heart disease in Quebec: impact of Canadian guidelines on clinical practice. Paediatr Child Health
2006; 11: 19–23.
29. Korean Ministry of Health & Welfare. Reimbursement guidelines. Data on file, 2012.
Abman, SH, Hansmann, G, Archer, SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation
2015; 132: 2037–2099.
Gaboli, M, de la Cruz, OA, de Aguero, MI, Moreno-Galdo, A, Perez, GP, de Querol, MS. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol
2014; 49: 490–502.
Farquhar, M, Fitzgerald, DA. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev
2010; 11: 149–153.
Kristensen, K, Stensballe, LG, Bjerre, J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child
2009; 94: 785–789.
Leslie, N, Bailey, L. Pompe disease. In: Pagon RA, Adam MP, Ardinger HH, et al (eds). Gene Reviews. Seattle, WA: University of Washington, Seattle; 1993-2017. Retrieved May 25, 2017 from https://www.ncbi.nlm.nih.gov/books/NBK1261/.
Alexander, PM, Eastaugh, L, Royle, J, Daley, AJ, Shekerdemian, LS, Penny, DJ. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease. J Paediatr Child Health
2012; 48: 395–401.
Donnerstein, RL, Berg, RA, Shehab, Z, Ovadia, M. Complex atrial tachycardias and respiratory syncytial virus infections in infants. J Pediatr
1994; 125: 23–28.
Fujita, S, Nakayama, Y, Usuda, K, Hanaoka, R, Yamada, K, Hatasaki, K. Catheter ablation for right ventricular outflow tract ventricular tachycardia induced by fever in a 7-year-old girl. Pediatr Cardiol
2010; 31: 128–131.
Esposito, S, Salice, P, Bosis, S, et al. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection. BMC Infect Dis
2010; 10: 305.
Yamamoto, A, Nakamura, K, Matsumoto, S, et al. VLCAD deficiency in a patient who recovered from ventricular fibrillation, but died suddenly of a respiratory syncytial virus infection. Pediatr Int
2013; 55: 775–778.
Grodin, JL, Wu, KS, Kitchell, EE, et al. Respiratory syncytial virus pneumonia treated with lower-dose palivizumab in a heart transplant recipient. Case Rep Cardiol
2012; 2012: 723407.
Mori, M, Morio, T, Ito, S, et al. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down’s syndrome. J Infect Chemother
2014; 20: 455–459.
Chavez-Bueno, S, Mejias, A, Merryman, RA, Ahmad, N, Jafri, HS, Ramilo, O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J
2007; 26: 1089–1093.
Michaels, MG, Fonseca-Aten, M, Green, M, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant
2009; 13: 451–456.
Kristensen, K, Hjuler, T, Ravn, H, Simoes, EA, Stensballe, LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis
2012; 54: 810–817.
Stagliano, DR, Nylund, CM, Eide, MB, Eberly, MD. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr
2015; 166: 703–709.e702.
Ashkenazi-Hoffnung, L, Dotan, M, Livni, G, Amir, J, Bilavsky, E. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants. Am J Infect Control
2014; 42: 991–995.
Tsang, R, Checchia, PA, Bronicki, R, Moffett, B, Morris, SA. Mortality and morbidity of respiratory syncytial virus bronchiolitis in congenital heart disease patients 1999-2012 – a population-based study. Congenit Heart Dis
2014; 9: 465.
Saadah, LM, Chedid, FD, Sohail, MR, Nazzal, YM, Al Kaabi, MR, Rahmani, AY. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Pharmacotherapy
2014; 34: 251–259.
Bergman, G, Haerskjold, A, Stensballe, LG, Kieler, H, Linder, M. Children with hemodynamically significant congenital heart disease can be identified through population-based registers. Clin Epidemiol
2015; 7: 119–127.
Figueras Aloy, J, Lopez Sastre, J, Medrano Lopez, C, et al. Spanish multidisciplinary consensus on the prevention of respiratory syncytial virus infection in children [in Spanish]. An Pediatr (Barc)
2008; 69: 63–71.
Khongphatthanayothin, A, Wong, PC, Samara, Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med
1999; 27: 1974–1981.
Hashmi, NA, Cosgrove, JF, MacMahon, P. Prophylaxis in RSV infection (palivizumab) – is it worthwhile?
Ir Med J
2000; 93: 284.
Granbom, E, Fernlund, E, Sunnegardh, J, Lundell, B, Naumburg, E. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease. Acta Paediatr
2014; 103: 840–845.
Danziger-Isakov, LA, Arslan, D, Sweet, S, Benden, C, Goldfarb, S, Wong, J. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant
2012; 16: 638–644.
Moynihan, JA, Kim, TY, Young, T, Checchia, PA. Rate of palivizumab administration in accordance with current recommendations among hospitalized children. J Pediatr Health Care
2004; 18: 224–227.
Anderson, KS, Mullally, VM, Fredrick, LM, Campbell, AL. Compliance with RSV prophylaxis: global physicians’ perspectives. Patient Prefer Adherence
2009; 3: 195–203.
Medrano, C, Garcia-Guereta, L, Grueso, J, et al. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study. Cardiol Young
2007; 17: 360–371.
Resch, B, Michel-Behnke, I. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol
2013; 28: 85–91.
Robinson, JL, Grenier, D, MacLusky, I, Allen, UD. Respiratory syncytial virus infections in pediatric transplant recipients: a Canadian Paediatric Surveillance Program study. Pediatr Transplant
2015; 19: 659–662.
Von Renesse, A, Schildgen, O, Klinkenberg, D, et al. Respiratory syncytial virus infection in children admitted to hospital but ventilated mechanically for other reasons. J Med Virol
2009; 81: 160–166.
Chi, H, Chang, IS, Tsai, FY, et al. Epidemiological study of hospitalization associated with respiratory syncytial virus infection in Taiwanese children between 2004 and 2007. J Formos Med Assoc
2011; 110: 388–396.
Svensson, C, Berg, K, Sigurs, N, Trollfors, B. Incidence, risk factors and hospital burden in children under five years of age hospitalised with respiratory syncytial virus infections. Acta Paediatr
2015; 104: 922–926.
Haynes, LM. Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis
2013; 208: S177–S183.
Tulloh, R. Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension. Paediatr Drugs
2009; 11: 115–128.
Medrano Lopez, C, Garcia-Guereta Silva, L, Lirio Casero, J, Garcia Perez, J. Respiratory infections, Down’s syndrome and congenital heart disease: the CIVIC 21 study. An Pediatr (Barc)
2009; 71: 38–46.
Chew, FT, Doraisingham, S, Ling, AE, Kumarasinghe, G, Lee, BW. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect
1998; 121: 121–128.
Lapena, S, Robles, MB, Castanon, L, et al. Climatic factors and lower respiratory tract infection due to respiratory syncytial virus in hospitalised infants in northern Spain. Eur J Epidemiol
2005; 20: 271–276.
Yusuf, S, Piedimonte, G, Auais, A, et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect
2007; 135: 1077–1090.
Carpenter, TC, Stenmark, KR. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatr Infect Dis J
2004; 23: S33–S40.
Tulloh, R, Flanders, L, Thompson, L, Feltes, T. Does RSV infection cause pulmonary hypertension in children undergoing cardiac surgery?
Arch Dis Child
2011; 96: A37–A38.
Ram, G, Chinen, J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol
2011; 164: 9–16.
Friedman, D, Wong, P, Fryzek, J, et al. Respiratory syncytial virus hospitalization risk in the second year of life by condition in children with congenital heart disease. Pediatric Academic Societies Annual Meeting, April 30 to May 3, 2016, Baltimore.
Wang, D, Li, A, Paes, B, Mitchell, I, Lanctôt, K. Comparison of first- and second-season palivizumab prophylaxis in patients with congenital airway anomalies (CAA) in the CARESS database (2005–2015). International Society for Pharmacoeconomics and Outcomes Research 21st Annual International Meeting, May 21–25, 2016, Washington, DC.